No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.

ABSTRACT:

Background

Studies over the past 10 years strongly support an association between skeletal muscle mass (SMM) depletion and outcome in metastatic colorectal cancer (mCRC). Factors influencing SMM changes over time are, however, poorly studied. We analyzed the impact of SMM on overall survival and chemotherapy toxicities in mCRC patients treated with first-line chemotherapy. Changes in weight and body composition were evaluated during follow-up.

Methods

Patients enrolled in the randomized phase II ACCORD trial comparing two chemotherapy regimens were screened. Body composition parameters (SMM, adipose tissue) were assessed prospectively with computed tomography (CT) imaging, and toxicities were recorded. Mixed models were used to assess weight and BC changes during 4 months of

SUBMITTER: Antoun S 

PROVIDER: S-EPMC6714393 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature